

Santiago Moreno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3756819/publications.pdf>

Version: 2024-02-01

200
papers

6,640
citations

76326

40
h-index

79698

73
g-index

220
all docs

220
docs citations

220
times ranked

8492
citing authors

#	ARTICLE	IF	CITATIONS
1	Carbapenemase-producing <i>Enterobacterales</i> infections in COVID-19 patients. <i>Infectious Diseases</i> , 2022, 54, 36-45.	2.8	18
2	Viruses and <i>Mycoplasma pneumoniae</i> are the main etiological agents of community-acquired pneumonia in hospitalized pediatric patients in Spain. <i>Pediatric Pulmonology</i> , 2022, 57, 253-263.	2.0	9
3	The hepatitis C cascade of care in HIV/hepatitis C virus coinfecting individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435.	2.2	8
4	SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment. <i>Aids</i> , 2022, 36, 161-168.	2.2	22
5	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab595.	0.9	3
6	Management of Comorbidities in Treated HIV Infection: A Long Way to Go. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106493.	2.5	17
7	Past and future of HIV infection. A document based on expert opinion. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 131-156.	1.3	2
8	Metabolic Snapshot of Plasma Samples Reveals New Pathways Implicated in SARS-CoV-2 Pathogenesis. <i>Journal of Proteome Research</i> , 2022, 21, 623-634.	3.7	14
9	Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens. <i>Frontiers in Immunology</i> , 2022, 13, 848630.	4.8	7
10	Relationship of Diet to Gut Microbiota and Inflammatory Biomarkers in People with HIV. <i>Nutrients</i> , 2022, 14, 1221.	4.1	6
11	Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV. <i>Frontiers in Immunology</i> , 2022, 13, 873408.	4.8	9
12	Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 827-841.	4.3	12
13	Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2. <i>Journal of Infection</i> , 2022, 85, 86-89.	3.3	7
14	Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. <i>EBioMedicine</i> , 2022, 80, 104072.	6.1	9
15	Interactions among the mycobiome, bacteriome, inflammation, and diet in people living with HIV. <i>Gut Microbes</i> , 2022, 14, .	9.8	8
16	Blood Bacterial Profiles Associated With Human Immunodeficiency Virus Infection and Immune Recovery. <i>Journal of Infectious Diseases</i> , 2021, 223, 471-481.	4.0	9
17	Hepatitis C and HIV combined screening in primary care: A cluster randomized trial. <i>Journal of Viral Hepatitis</i> , 2021, 28, 345-352.	2.0	7
18	Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 238-243.	6.0	63

#	ARTICLE	IF	CITATIONS
19	Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers. <i>Emerging Microbes and Infections</i> , 2021, 10, 493-496.	6.5	15
20	Fecal microbiota transplantation in HIV: A pilot placebo-controlled study. <i>Nature Communications</i> , 2021, 12, 1139.	12.8	49
21	Effect of the Use of Galectin-9 and Blockade of the TIM-3 Receptor in the Latent Cellular Reservoir of HIV-1. <i>Journal of Virology</i> , 2021, 95, .	3.4	12
22	Exploiting the Microbiota for the Diagnosis of Anal Precancerous Lesions in Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2021, 224, 1247-1256.	4.0	8
23	Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment. <i>Aids</i> , 2021, 35, 1283-1293.	2.2	13
24	Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004-2018. <i>PLoS ONE</i> , 2021, 16, e0249864.	2.5	25
25	Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25732.	3.0	14
26	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	2.2	4
27	Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab251.	0.9	0
28	Redefining therapeutic success in HIV patients: an expert view. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2501-2518.	3.0	15
29	Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1678-1684.	6.0	34
30	Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study). <i>Mycoses</i> , 2021, 64, 1334-1345.	4.0	12
31	COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. <i>HIV Medicine</i> , 2021, 22, 867-876.	2.2	21
32	Cryptococcal infection in HIV-infected patients with CD4+ T-cell counts under 100/µL diagnosed in a high-income country: a multicentre cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1171.e1-1171.e7.	6.0	2
33	Differences in epidemiology and mortality between men and women with HIV infection in the CoRIS cohort from 2004 to 2014. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 372-382.	0.3	1
34	Antiviral therapy and immunotherapy of COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 53-59.	1.3	0
35	Diferencias epidemiológicas y de mortalidad entre hombres y mujeres con infección por VIH en la cohorte CoRIS entre los años 2004 y 2014. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 372-382.	0.5	5
36	Implementation of a lung cancer screening initiative in HIV-infected subjects. <i>PLoS ONE</i> , 2021, 16, e0260069.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> ,the, 2020, 7, e565-e573.	4.7	42
38	Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells. <i>Biochemical Pharmacology</i> , 2020, 182, 114231.	4.4	5
39	Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3004-3014.	3.0	5
40	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2020, 173, 536-541.	3.9	280
41	Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects. <i>Frontiers in Immunology</i> , 2020, 11, 581307.	4.8	6
42	A NKp80-Based Identification Strategy Reveals that CD56neg NK Cells Are Not Completely Dysfunctional in Health and Disease. <i>IScience</i> , 2020, 23, 101298.	4.1	14
43	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHT study. <i>Lancet HIV</i> ,the, 2020, 7, e740-e751.	4.7	58
44	Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance. <i>International Journal of Infectious Diseases</i> , 2020, 101, 24-28.	3.3	16
45	Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey. <i>EClinicalMedicine</i> , 2020, 27, 100539.	7.1	15
46	“It made me more confident that I have it under control” Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. <i>PLoS ONE</i> , 2020, 15, e0232473.	2.5	7
47	Frailty, markers of immune activation and oxidative stress in HIV infected elderly. <i>PLoS ONE</i> , 2020, 15, e0230339.	2.5	18
48	Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1604-1610.	3.0	8
49	Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21. <i>Journal of Clinical Medicine</i> , 2020, 9, 760.	2.4	13
50	Changes in inflammatory biomarkers in SWORD-1 and SWORD-2 studies. <i>Lancet HIV</i> ,the, 2020, 7, e158.	4.7	3
51	Sex Differences in People Aging With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 284-291.	2.1	22
52	New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144. <i>Scientific Reports</i> , 2020, 10, 2937.	3.3	14
53	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1294-1300.	3.0	12
54	Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2). <i>PLoS ONE</i> , 2020, 15, e0226724.	2.5	2

#	ARTICLE	IF	CITATIONS
55	Gender-based vulnerability in women who inject drugs in a harm reduction setting. PLoS ONE, 2020, 15, e0230886.	2.5	20
56	Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound. Scientific Reports, 2020, 10, 22286.	3.3	6
57	Travelling with HIV in the XXI century: Case report and narrative review. Travel Medicine and Infectious Disease, 2020, 38, 101921.	3.0	1
58	Recommendations for the early diagnosis of suspected human immunodeficiency virus infection in the emergency department and the referral of patients for follow-up: a consensus statement of the Spanish Society of Emergency Medicine (SEMES). Emergencias, 2020, 32, 416-426.	0.6	5
59	Telepharmacy. Ready for its global implementation?. Farmacia Hospitalaria, 2020, 44, 125-126.	0.6	3
60	Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study). Clinical Infectious Diseases, 2019, 68, 120-130.	5.8	31
61	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 151-159.	0.5	7
62	Profilaxis preexposición al VIH en España: situación política y administrativa. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 656-660.	0.5	4
63	Impact of a structured HIV testing program in a hospital emergency department and a primary care center. PLoS ONE, 2019, 14, e0220375.	2.5	18
64	Las pérdidas de seguimiento de las personas con infección por VIH: un punto débil en el continuo de cuidados. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 359-360.	0.5	0
65	Selective miRNA Modulation Fails to Activate HIV Replication in In Vitro Latency Models. Molecular Therapy - Nucleic Acids, 2019, 17, 323-336.	5.1	7
66	Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. HIV Medicine, 2019, 20, 648-656.	2.2	12
67	High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. International Journal of Drug Policy, 2019, 72, 181-188.	3.3	29
68	Outcome of an HIV education program for primary care providers: Screening and late diagnosis rates. PLoS ONE, 2019, 14, e0218380.	2.5	12
69	Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients. PLoS ONE, 2019, 14, e0220459.	2.5	10
70	Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLoS ONE, 2019, 14, e0221598.	2.5	7
71	Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population. Epigenomics, 2019, 11, 501-509.	2.1	21
72	Follow-up losses of people with HIV infection: A weak point in the continuum of care. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2019, 37, 359-360.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Two-drug vs. three-drug combinations for HIV: Do we have enough data to make the switch?. <i>HIV Medicine</i> , 2019, 20, 2-12.	2.2	57
74	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 151-159.	0.3	1
75	Aerosolized Lipid Amphotericin B for Complementary Therapy and/or Secondary Prophylaxis in Patients with Invasive Pulmonary Aspergillosis: A Single-Center Experience. <i>Mycopathologia</i> , 2019, 184, 239-250.	3.1	6
76	Durability of First-Line Antiretroviral Regimens in the era of Integrase Inhibitors: A Cohort of HIV-Positive Individuals in Spain, 2014-2015. <i>Antiviral Therapy</i> , 2019, 24, 167-175.	1.0	6
77	High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use. <i>Virus Research</i> , 2019, 264, 40-44.	2.2	6
78	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , 2019, 33, 2013-2024.	2.2	13
79	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 292-300.	2.1	24
80	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 314-320.	2.1	6
81	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 667-671.	3.1	14
82	HIV infection epidemiology: a change of scenery. <i>European Geriatric Medicine</i> , 2019, 10, 169-174.	2.8	4
83	Estrategias de curación de la infección por VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 265-273.	0.5	5
84	Infección por VIH en el primer mundo: ¿Qué nos queda pendiente?. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2019, 4, 47-50.	0.0	0
85	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 580-587.	0.5	4
86	Are toxicities of current nucleosides still a concern?. <i>Lancet HIV</i> , 2018, 5, e156-e157.	4.7	0
87	Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota. <i>Aids</i> , 2018, 32, 1229-1237.	2.2	25
88	Maraviroc Is Associated with Latent HIV-1 Reactivation through NF- κ B Activation in Resting CD4 ⁺ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. <i>Journal of Virology</i> , 2018, 92, .	3.4	36
89	Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial. <i>Clinical Microbiology and Infection</i> , 2018, 24, 900-907.	6.0	20
90	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV-HBV-Coinfected Patients in the EuroSIDA Study. <i>Antiviral Therapy</i> , 2018, 23, 405-413.	1.0	5

#	ARTICLE	IF	CITATIONS
91	Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc. <i>Journal of Virology</i> , 2018, 92, .	3.4	2
92	High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit. <i>Aids</i> , 2018, 32, 1157-1163.	2.2	3
93	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y MicrobiologÍa ClÍnica</i> , 2018, 36, 268-276.	0.5	6
94	Increased frequencies of Th17 cells and IL17a-producing regulatory T-cells preceding the immunodiscordant response to antiretroviral treatment. <i>Journal of Infection</i> , 2018, 76, 86-92.	3.3	9
95	The functional consequences of the microbiome in HIV. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 88-94.	3.8	13
96	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 102-109.	2.1	2
97	Detecci3n temprana. <i>Enfermedades Infecciosas Y MicrobiologÍa ClÍnica</i> , 2018, 36, 35-39.	0.5	13
98	HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. <i>PLoS ONE</i> , 2018, 13, e0204795.	2.5	10
99	Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017. <i>PLoS ONE</i> , 2018, 13, e0204738.	2.5	23
100	Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients. <i>PLoS ONE</i> , 2018, 13, e0196201.	2.5	16
101	Interplay between gut microbiota metabolism and inflammation in HIV infection. <i>ISME Journal</i> , 2018, 12, 1964-1976.	9.8	48
102	Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2927-2935.	3.0	17
103	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw833.	5.8	28
104	Combined Effect of Sex and Age in Response to Antiretroviral Therapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2017, 22, 21-29.	1.0	4
105	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 29-32.	1.1	5
106	How can the gut microbiota affect immune recovery in HIV-infected individuals?. <i>Future Microbiology</i> , 2017, 12, 195-199.	2.0	8
107	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y MicrobiologÍa ClÍnica</i> , 2017, 35, 377-383.	0.5	11
108	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV,the</i> , 2017, 4, e251-e259.	4.7	10

#	ARTICLE	IF	CITATIONS
109	Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, e36-e44.	2.1	10
110	The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatins-1. <i>Scientific Reports</i> , 2017, 7, 2385.	3.3	38
111	Frailty and physical function in older HIV-infected adults. <i>Age and Ageing</i> , 2017, 46, 522-526.	1.6	47
112	¿Es el momento de poner en marcha nuevas estrategias de prevención de la infección por VIH en España?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 271-272.	0.5	3
113	Management of a tracheoesophageal fistula in a patient with AIDS. <i>Asian Cardiovascular and Thoracic Annals</i> , 2017, 25, 226-228.	0.5	0
114	The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects. <i>Mucosal Immunology</i> , 2017, 10, 1279-1293.	6.0	103
115	Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
116	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 491-496.	0.3	0
117	HIV, HPV, and microbiota. <i>Aids</i> , 2017, 31, 591-594.	2.2	29
118	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 377-383.	0.3	0
119	The changing epidemiology of tuberculosis in a Spanish tertiary hospital (1995–2013). <i>Medicine (United Tj ETQq1,1 0.784314 rgB</i>	1.0	11
120	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 88-99.	0.5	12
121	Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 235-239.	3.0	27
122	Simplification to dual therapy (atazanavir/ritonavir+lamivudine) versus standard triple therapy [atazanavir/ritonavir+two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 246-253.	3.0	57
123	Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM. <i>PLoS ONE</i> , 2017, 12, e0188851.	2.5	15
124	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2862-2868.	3.0	5
125	Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. <i>PLoS ONE</i> , 2017, 12, e0184329.	2.5	6
126	Highlights in HIV, 2016. <i>Revista Espanola De Quimioterapia</i> , 2017, 30 Suppl 1, 13-15.	1.3	0

#	ARTICLE	IF	CITATIONS
127	Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE, 2016, 11, e0164455.	2.5	7
128	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathogens, 2016, 12, e1005381.	4.7	37
129	Low Co-infection Rate in Children With Community-Acquired Pneumonia in Spain. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
130	Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. Aids, 2016, 30, 1385-1392.	2.2	167
131	Beyond Undetectable Viral Load: Effect of Nucleotides on Inflammation. EBioMedicine, 2016, 13, 31-32.	6.1	2
132	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013. Journal of Infection, 2016, 72, 587-596.	3.3	60
133	Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. Journal of Infection, 2016, 72, 738-744.	3.3	48
134	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 214-221.	2.1	22
135	Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals. EBioMedicine, 2016, 8, 203-216.	6.1	93
136	HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseases. Scientific Reports, 2016, 6, 26192.	3.3	50
137	Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. European Journal of Neurology, 2016, 23, 919-925.	3.3	34
138	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. Open Forum Infectious Diseases, 2016, 3, ofw097.	0.9	37
139	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal of Epidemiology, 2016, 45, 2038-2049.	1.9	43
140	Oxidative Stress Predicts All-Cause Mortality in HIV-Infected Patients. PLoS ONE, 2016, 11, e0153456.	2.5	40
141	Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US. Antiviral Therapy, 2015, 20, 21-28.	1.0	23
142	Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Scientific Reports, 2015, 5, 16445.	3.3	41
143	Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF- κ B-dependent mechanism. Scientific Reports, 2015, 5, 12442.	3.3	53
144	Shorter Telomere Length Predicts Poorer Immunological Recovery in Virologically Suppressed HIV-1-Infected Patients Treated With Combined Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 21-29.	2.1	23

#	ARTICLE	IF	CITATIONS
145	Monitoring the CD4/CD8 ratio: a promising indicator of disease progression in HIV-infected individuals?. <i>Future Virology</i> , 2015, 10, 1-4.	1.8	5
146	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015, 120, 79-84.	4.1	16
147	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , 2015, 2, e335-e343.	4.7	52
148	Dual treatment with atazanavir+ritonavir plus lamivudine versus triple treatment with atazanavir+ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 775-784.	9.1	122
149	Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. <i>Antiviral Research</i> , 2015, 123, 163-171.	4.1	10
150	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.5	10
151	Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. <i>Clinical Microbiology and Infection</i> , 2015, 21, 104.e1-104.e5.	6.0	7
152	Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. <i>Mucosal Immunology</i> , 2015, 8, 760-772.	6.0	255
153	Regional differences in self-reported HIV care and management in the EuroSIDA study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19504.	3.0	4
154	Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19800.	3.0	1
155	Incremental cost per newly diagnosed HIV infection (NDHI): routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS). <i>Journal of the International AIDS Society</i> , 2014, 17, 19606.	3.0	4
156	HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. <i>PLoS Pathogens</i> , 2014, 10, e1004078.	4.7	495
157	Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. <i>Journal of Infectious Diseases</i> , 2014, 210, 354-362.	4.0	284
158	Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1080-1084.	1.2	13
159	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 700-708.	1.2	11
160	The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. <i>HIV Medicine</i> , 2014, 15, 40-49.	2.2	124
161	Reactivation of Latent HIV-1 by Bryostatin-1 in the Presence of Antiretroviral Drugs. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A285-A285.	1.1	0
162	Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio. <i>PLoS ONE</i> , 2014, 9, e85798.	2.5	175

#	ARTICLE	IF	CITATIONS
163	Bryostatins Activates HIV-1 Latent Expression in Human Astrocytes through a PKC and NF- κ B-Dependent Mechanism. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A285-A285.	1.1	2
164	Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3134-3141.	3.0	51
165	Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1916-1919.	3.0	6
166	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2014, 83, 134-141.	1.1	112
167	Comparison of routine versus targeted HIV testing strategies: coverage and estimated missed infections in emergency room and primary care centre. <i>Journal of the International AIDS Society</i> , 2014, 17, 19671.	3.0	5
168	Extra-pulmonary tuberculosis: differential aspects and role of 16S-rRNA in urine. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 478-485.	1.2	18
169	Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis. <i>AIDS Reviews</i> , 2014, 16, 213-22.	1.0	18
170	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	8.4	256
171	The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. <i>Aids</i> , 2013, 27, 1513-1516.	2.2	125
172	Definition of Advanced Age in HIV Infection: Looking for an Age Cut-Off. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1000-1006.	1.1	56
173	All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection. <i>Journal of Hepatology</i> , 2012, 57, 743-751.	3.7	100
174	ACP Journal Club. Earlier initiation of antiretroviral therapy after start of antituberculosis therapy reduced mortality in HIV. <i>Annals of Internal Medicine</i> , 2012, 156, JC3-2.	3.9	0
175	Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected. <i>PLoS ONE</i> , 2011, 6, e27864.	2.5	84
176	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , 2010, 24, 123-137.	2.2	360
177	Bryostatins-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency. <i>Current HIV Research</i> , 2010, 8, 418-429.	0.5	107
178	Medical and Societal Consequences of Late Presentation. <i>Antiviral Therapy</i> , 2010, 15, 9-15.	1.0	61
179	Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. <i>Clinical Therapeutics</i> , 2010, 32, 2232-2245.	2.5	3
180	Effect of 24 weeks of intensification with a CCR5-antagonist on the decay of the HIV-1 latent reservoir. <i>Journal of the International AIDS Society</i> , 2010, 13, O13-O13.	3.0	1

#	ARTICLE	IF	CITATIONS
181	Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen. <i>Journal of the International AIDS Society</i> , 2010, 13, P150.	3.0	2
182	Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA ≤ 50 copies/mL. <i>Journal of the International AIDS Society</i> , 2010, 13, P49-P49.	3.0	0
183	Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study). <i>Journal of the International AIDS Society</i> , 2010, 13, P79-P79.	3.0	0
184	CD4 response, lipid changes and liver outcome in 506 patients receiving nevirapine-based regimens for a median of 9 years. <i>Journal of the International AIDS Society</i> , 2010, 13, P81.	3.0	1
185	Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients. <i>Journal of the International AIDS Society</i> , 2010, 13, P91-P91.	3.0	1
186	The future of antiretroviral therapy: challenges and needs. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 827-835.	3.0	46
187	Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 249-258.	2.0	26
188	Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain. <i>HIV Clinical Trials</i> , 2009, 10, 394-402.	2.0	12
189	Delayed Diagnosis of HIV Infection in a Multicenter Cohort: Prevalence, Risk Factors, Response to HAART and Impact on Mortality. <i>Current HIV Research</i> , 2009, 7, 224-230.	0.5	96
190	Disorders of body fat distribution in HIV-1-infected patients. <i>AIDS Reviews</i> , 2009, 11, 126-34.	1.0	26
191	Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. <i>International Journal of Tuberculosis and Lung Disease</i> , 2008, 12, 1393-400.	1.2	31
192	Didanosine Enteric-Coated Capsule. <i>Drugs</i> , 2007, 67, 1441-1462.	10.9	16
193	The Magnitude of Week 4 HCV RNA Decay on Pegylated Interferon/Ribavirin Accurately Predicts Virological Failure in Patients with Genotype 1. <i>Antiviral Therapy</i> , 2007, 12, 401-406.	1.0	9
194	Antiretroviral therapy in AIDS patients with tuberculosis. <i>AIDS Reviews</i> , 2006, 8, 115-24.	1.0	12
195	Liver transplantation in HIV-infected recipients. <i>Liver Transplantation</i> , 2005, 11, 76-81.	2.4	45
196	High Rate of Didanosine-Related Mitochondrial Toxicity in HIV/HCV-Coinfected Patients Receiving Ribavirin. <i>Antiviral Therapy</i> , 2004, 9, 133-138.	1.0	88
197	Voriconazole in the Treatment of Invasive Mold Infections in Transplant Recipients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003, 22, 408-413.	2.9	65
198	Stavudine Once Daily. <i>Drugs</i> , 2002, 62, 2675-2676.	10.9	0

#	ARTICLE	IF	CITATIONS
199	Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transplantation, 2002, 8, 1065-1070.	2.4	163
200	ASPERGILLUS ANTIGENEMIA SANDWICH-ENZYME IMMUNOASSAY TEST AS A SERODIAGNOSTIC METHOD FOR INVASIVE ASPERGILLOSIS IN LIVER TRANSPLANT RECIPIENTS1. Transplantation, 2001, 71, 145-149.	1.0	103